RANDOMISED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM
- 1 August 1988
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 332 (8606), 293-298
- https://doi.org/10.1016/s0140-6736(88)92354-9
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Thrombolytic therapy of acute pulmonary embolism: Current status and future potentialJournal of the American College of Cardiology, 1987
- Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activatorJournal of the American College of Cardiology, 1987
- A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris.Circulation, 1987
- Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy.Circulation, 1987
- Perspectives on Treatment of Acute Pulmonary Embolism with Tissue Plasminogen ActivatorSeminars in Thrombosis and Hemostasis, 1987
- ACUTE PULMONARY EMBOLISM TREATED WITH TISSUE PLASMINOGEN ACTIVATORThe Lancet, 1986
- The sulphite precipitation method for fibrinogen measurement; Its use on small samples in the presence of fibrinogen degradation productsClinica Chimica Acta; International Journal of Clinical Chemistry, 1976
- Artificial PacemakersCirculation, 1973
- A Rapid, Simple, Sensitive Method for Measuring Fibrinolytic Split Products in Human SerumExperimental Biology and Medicine, 1969
- Individual Comparisons by Ranking MethodsBiometrics Bulletin, 1945